Trial Profile

Multicenter Phase II trial of erlotinib for elderly patients with advanced or recurrent non-small cell lung cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms LOGiK-0802

Most Recent Events

01 Jun 2016 Results published in the Anticancer Research
02 Sep 2013 Planned end date changed from 1 Jul 2014 to 31 Jan 2015 as reported by University Hospital Medical Information Network - Japan record.
05 Mar 2013 Planned end date changed from 1 Jan 2014 to 1 Jul 2014 as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com